Active	Status	Sponsor type	Region	Phase	Filter
11 Active 3 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Xiaochun
NCT04135677: Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO	Recruiting	4	826	RoW	Rivaroxaban, new oral anticoagulation, DAPT, dual antiplatelet therapy	Shanghai Zhongshan Hospital	Left Atrial Appendage Thrombosis, Thrombi, Stroke	10/24	10/24
NCT04890795: A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer	Recruiting	1/2	237	RoW	AL8326 tablets, AL8326	Advenchen Laboratories Nanjing Ltd.	Small Cell Lung Cancer	09/21	09/21
PDL1-BEY-LUNG, NCT05325684: PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer	Not yet recruiting	1/2	30	NA	PD-L1 inhibitor	The Affiliated Hospital of Qingdao University	Efficacy, Safety	12/23	12/23
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors	Recruiting	1/2	320	RoW	TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab	Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb	Advanced Cancer	02/25	05/25
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy	Recruiting	1	40	RoW	TQB2858 injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Cervical Cancer	05/23	07/23
NCT03966456: Real World Study of Four PD-1 Agents in China	Recruiting	N/A	500	RoW	Chemotherapy, targeting therapy	The Affiliated Hospital of Qingdao University	Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma	06/21	06/23
NCT05391191: Safety and Feasibility of TRISKELE in Severe AS	Recruiting	N/A	7	RoW	MitrAssist TRISKELE® transcatheter aortic valve system	Shanghai Zhongshan Hospital	Aortic Valve Disease	03/23	03/23
NCT04550637: A Multi-center Study of Apixaban(APPROACH)	Recruiting	N/A	200	RoW	Oral apixaban	Shanghai Zhongshan Hospital	Evaluate the Safety and Efficacy of Apixaban	12/23	12/24
NCT04782622: The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy	Recruiting	N/A	60	RoW	Apatinib+Camrelizumab	The Affiliated Hospital of Qingdao University	Lung Cancer	01/22	03/23
Jiang, Man
NCT04713059: Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)	Recruiting	N/A	62	RoW	FGFR2	The Affiliated Hospital of Qingdao University	Gastric or Gastro-oesophageal Junction Carcinoma, Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma, Second-line Therapy	01/21	01/23
NCT03966456: Real World Study of Four PD-1 Agents in China	Recruiting	N/A	500	RoW	Chemotherapy, targeting therapy	The Affiliated Hospital of Qingdao University	Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors, Malignant Melanoma	06/21	06/23